A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting by Chrun, Tiphany et al.
ARTICLE OPEN
A Rift Valley fever virus Gn ectodomain-based DNA vaccine
induces a partial protection not improved by APC targeting
Tiphany Chrun1,2, Sandra Lacôte2, Céline Urien1, Luc Jouneau1, Céline Barc3, Edwige Bouguyon1, Vanessa Contreras4,
Audrey Ferrier-Rembert5, Christophe N. Peyreﬁtte5, Nuria Busquets6, Enric Vidal6, Joan Pujols6, Philippe Marianneau2 and
Isabelle Schwartz-Cornil1
Rift Valley fever virus, a phlebovirus endemic in Africa, causes serious diseases in ruminants and humans. Due to the high
probability of new outbreaks and spread to other continents where competent vectors are present, vaccine development is an
urgent priority as no licensed vaccines are available outside areas of endemicity. In this study, we evaluated in sheep the protective
immunity induced by DNA vaccines encoding the extracellular portion of the Gn antigen which was either or not targeted to
antigen-presenting cells. The DNA encoding untargeted antigen was the most potent at inducing IgG responses, although not
neutralizing, and conferred a signiﬁcant clinical and virological protection upon infectious challenge, superior to DNA vaccines
encoding the targeted antigen. A statistical analysis of the challenge parameters supported that the anti-eGn IgG, rather than the T-
cell response, was instrumental in protection. Altogether, this work shows that a DNA vaccine encoding the extracellular portion of
the Gn antigen confers substantial—although incomplete—protective immunity in sheep, a natural host with high preclinical
relevance, and provides some insights into key immune correlates useful for further vaccine improvements against the Rift Valley
fever virus.
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INTRODUCTION
The Rift Valley Fever Virus (RVFV) is a zoonotic phlebovirus
(Phenuiviridae) transmitted by mosquitoes, causing serious dis-
eases in humans and ruminants. In humans, RVFV usually induces
a febrile illness, and sometimes hepatitis, hemorrhagic fever,
retinitis or encephalitis, leading to death. In ruminants, RVFV is
responsible for abortions in pregnant ewes and a high die-off rate
in young sheep (see ref. 1 for review). RVFV has caused recurrent
outbreaks in Sub-Saharan Africa since 1931 and later spread to the
Arabian Peninsula, raising awareness of the potentiality for
introduction to other continents where a large array of competent
insects would embed the virus in the ecosystem with devastating
health, social and economic consequences. Attenuated and
inactivated RVFV vaccines are commercialized for ruminants in
enzootic countries. However, the risk of reversion of attenuated
vaccines renders their registration unlikely in Europe and the
United States and the need for repeated injections of inactivated
vaccines is not compatible with herd management in most
countries. The 2017 WHO Blueprint list cites RVFV as one of the 10
priority pathogens for which a low-cost, safe, stable and highly
effective vaccine is urgently needed (http://www.who.int/
blueprint/priority-diseases/en/).
The M segment of the tripartite negative stranded RVFV RNA
genome encodes for a polypeptide generating the Gn and Gc
glycoproteins which are involved in viral attachment and fusion,
respectively. Neutralizing antibodies (NAbs) are directed to both
Gn and Gc.2 Gc is located within the glycoprotein shell whereas
Gn is exposed on the outside, indicating that Gn is a major target
of NAbs.3 Importantly, anti-Gn and Gc NAbs can confer protection
by passive transfer.4 Expression of the Gn ectodomain allowed
production of a secreted form (eGn) that, after injection as a
protein vaccine in mice, conferred full protection against RVFV,5
indicating that eGn is a promising antigen candidate for a subunit
vaccine. Furthermore a DNA vaccine encoding eGn was found to
be partially protective in mice, despite low levels of NAbs.6 Finally,
CD8+ T-cell responses against the Gn/Gc proteins were identiﬁed
in the context of protective immune responses,7 but their role in
protection is unclear.
DNA vaccines present many of the qualities desired for a new
RVFV vaccine: they show good stability outside cold chain, they
can be prepared for emergency vaccine banks, they are
noninfectious and safe, they allow differentiation of infected from
vaccinated animals (DIVA), they are easy to construct, their
manufacture is feasible at large scale and they have the potential
to be cost effective to produce, especially when compared to
recombinant proteins.8,9 However, whereas DNA vaccines induce
high T-cell and Ab responses in rodent models, they usually
display low immunogenicity properties in other mammals
including ruminants and humans.10 Improvement of DNA vaccine
immunogenicity has been achieved by enhancing the in vivo
delivery with electroporation in skin and muscle,11 by adding
genetically encoded adjuvants such as granulocyte-macrophage
colony-stimulating factor (GM-CSF),8 as well as by fusing the
encoded vaccine antigen to a single chain fragment variable
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(scFv), or a chemokine, for targeting a receptor expressed on
antigen-presenting cells (APCs).12–16 Among APCs, conventional
dendritic cells (cDCs) appear as the key cell type involved in APC-
targeting efﬁcacy.17 In mice cDCs have been classiﬁed in two
major subsets, the cDC1 and cDC2, with the cDC1 subset excelling
in CD8+ T and T helper cell type 1 (Th1) CD4+ T-cell activation and
the cDC2 subset promoting the T helper cell type 2 and 17 (Th2
and Th17) CD4+ T-cell differentiation.18 Homologous cDC1 and
cDC2 subsets have been identiﬁed in other species, i.e., in humans,
monkey, sheep and pig, and they can be distinguished based on a
conserved trans-species phenotype with cDC1 being CADM1hi-
SIRPlo and cDC2 being CADM1loSIRPhi.19,20 A large number of
studies, primarily conducted in mice, revealed that targeting
antigens to cDCs using protein or DNA vaccines results in
enhancing and even biasing the type of immune responses,
depending on both the targeted cDC subset and the nature of the
targeted receptor (see refs.21,22 for reviews). The most compre-
hensively studied molecule for APC targeting is DEC20522 which is
expressed on cDCs in many species including ruminants23 and is
overexpressed on cDC1s at least in mice. The targeting of different
antigens to DEC205 in DNA vaccination of mice12,1324,25 resulted in
enhanced Ab, CD4+ and CD8+ T-cell responses. In addition in a
study comparing different targeted receptors using chimeric
protein vaccines, CD11c, the general marker of DC, revealed to be
a particularly suitable receptor for inducing high humoral
responses26 and was also efﬁcient at enhancing both Ab and T-
cell responses with DNA vaccines in mice.14 Despite the
spectacular promises from mouse models, the improvement of
protective immunity by APC-targeting remains to be documented
in large mammals in order to translate this approach to humans
and veterinary applications.27
Based on this context, we constructed DNA vaccines encoding
the RVFV eGn in fusion with a scFv anti-ovine DEC205 and a scFv
anti-ovine CD11c and compared them to a DNA vaccine encoding
untargeted eGn for their capacity to induce protective immunity
in sheep. The vaccines were delivered in the dermis, a tissue
densely inhabited with DCs, together with an adjuvant plasmid
encoding for ovine GM-CSF.28 Surface electroporation (SEP) was
used to promote DNA transfection in skin cells and immunogeni-
city.29 Interestingly, we found that the DNA encoding eGn
targeted to DEC205 and not to CD11c promoted the interferon-
γ (IFNγ) T-cell responses as compared to DNA encoding
untargeted eGn, thus indicating that APC targeting can improve
T-cell responses outside the mouse species. However, DNA
encoding untargeted eGn was the most efﬁcient at inducing
anti-eGn immunoglobulin G (IgG) responses, although not
neutralizing. This latter plasmid was efﬁcient at inducing
signiﬁcant protection against infectious challenge to a higher
extent than the one encoding DEC205- and CD11c-targeted eGn.
Furthermore, the anti-eGn IgG levels correlated with protection,
suggesting that IgG responses rather than T-cell responses are
important in the protective immunity conferred by eGn encoding
DNA vaccines.
RESULTS
Generation and validation of scFvs for targeting RVFV eGn to
ovine DEC205 and CD11c receptors
In order to construct DNA vaccines encoding RVFV eGn targeted
to sheep APCs, we derived scFv sequences from two murine
hybridomas secreting monoclonal antibodies (mAbs) against
ovine DEC205 or CD11c. The scFv sequences were fused to
mCherry and the fusion proteins were expressed in HEK293 cells.
We evaluated the binding capacities to sheep cDC subsets of
scDEC-mCherry and scCD11c-mCherry fusion proteins relatively to
a scCtlr-mCherry control, and we compared their staining proﬁles
to the ones of their parental mAb. For that purpose, we collected
lymph-draining sheep skin at steady state using the pseudo-
afferent lymph cannulation technique23 and we isolated low-
density cells; these cells are strongly enriched in skin-migrated
cDCs which are physiologically relevant cell targets in the context
of skin vaccination and which include the cDC1 and
cDC2 subtypes, identiﬁed as FSChi CD1b+ CADM1hi and FSChi
CD1b+ CADM1lo cells respectively (Fig. 1a).20,23 A staining with the
parental anti-DEC205 mAb shows that cDC1s express slightly more
DEC205 than cDC2s, relatively to an isotype control (Fig. 1b), as we
previously published.23 This ﬁnding is in agreement with the
slightly higher expression of DEC205 on mouse skin-migrated
cDC1s than on cDC2s.30 The staining of cDC1s with the parental
anti-CD11c mAb appears heterogeneous and presented two
peaks, whereas the staining of cDC2 is homogenous. The scDEC-
mCherry and scCD11c-mCherry fusions presented a similar
staining pattern as the one obtained with the parental mAbs
(Fig. 1c). Thus, the anti-DEC205 and CD11c scFvs can be used to
create constructs to target RVFV eGn to the corresponding sheep
molecules.
Construction, characterization and expression of anti-DEC205 and
anti-CD11c scFvs fused to RVFV eGn
Synthetic genes were designed in order to generate vaccine
plasmids encoding untargeted eGn (peGn) and eGn targeted to
DEC205 or to CD11c using the validated scFv sequences (pscDEC-
eGn and pscCD11c-eGn). As shown in Fig. 2a, peGn includes the
eGn sequence (nt 411 to nt 1763 of the RVFV M segment,
ZH501 strain) beginning with its natural signal peptide (nt 411 to
477) whereas the plasmids encoding APC-targeted eGn include
the VH signal peptide of the original mAb, the scFv sequence and
the eGn sequence from nt 477 to nt 1763 which is devoid of
transmembrane domains for allowing the fusion protein secretion.
The plasmids were transfected in HEK293 cells and the cell
lysates and supernatants were collected for assessing eGn protein
expression in vitro. Bands corresponding to untargeted eGn
(48.8 kDa) and to scDEC-eGn and scCD11c-eGn protein fusions
(76.3 and 78.6 kDa respectively) were detected at their expected
predicted size in western blot using an anti-RVFV hyperimmune
mouse ascitic ﬂuid (HMAF, Fig. 2b). We could not detect the three
proteins in the concentrated supernatants by western blot,
possibly due to too limited amounts of eGn that could be
detectable by the anti-RVFV HMAF on the nitrocellulose mem-
brane. However, in a dot plot assay where 25 times more volume
was loaded, the three supernatants from the eGn-expressing
plasmid reacted with the anti-RVFV HMAF (Fig. 2c). Furthermore,
when low-density skin lymph cells were incubated with the
concentrated supernatants, the binding of scDEC-eGn and
scCD11c-eGn could clearly be detected by the anti-RVFV HMAF
on FSChi cells, which mainly correspond to cDCs (Fig. 2d). This
experiment indicates that our scFv-based construct can target eGn
to sheep skin DCs.
Finally, we assessed whether peGn, pscDEC-eGn and pscCD11c-
eGn can be expressed in vivo, and to what relative levels, in the
sheep host species. We chose to deliver the plasmids into sheep
skin by injection in the dermis followed by SEP, as done previously
to successfully immunize mice and pigs with DNA encoding for
APC-targeted vaccines.15,16 After having determined the optimal
plasmid delivery parameters using a ﬁreﬂy luciferase expressing
plasmid and escalating electric ﬁeld values (supplementary
material 1), we detected the expression of peGn, pscDEC-eGn
and pscCD11c-eGn delivered in sheep skin, using the sensitive
real-time reverse transcription-polymerase chain reaction (qRT-
PCR) technique, 48 h post administration (Fig. 2e). eGn messenger
RNA (mRNA) could be detected in all injected biopsies (from Cq 26
to Cq 32.8, data not shown) and no signal could be detected in the
non-transfected skin. After normalization with the RPS24 reference
gene, we found that eGn mRNA expression was quite variable for
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the same plasmid, precluding any statistical analysis. Nevertheless,
pscDEC and pscCD11c-eGn tended to be less expressed or were at
least not more expressed than peGn in sheep skin (Fig. 2e).
In conclusion, pscDEC-eGn and pscCD11c-eGn express func-
tional fusion proteins capable of targeting eGn to sheep APCs and
the mRNA expression of peGn, pscDEC-eGn and pscCD11c-eGn is
detectable in pig skin upon electroporation in vivo.
Immunization with pscDEC-eGn promotes the eGn-speciﬁc IFNγ
T-cell responses
The three RVFV DNA vaccines, i.e., peGn, pscDEC-eGn and
pscCD11c-eGn, were compared for their immunogenicity in sheep.
Each DNA vaccine was combined to pGM-CSF as an adjuvant and
was inoculated 3 times intradermally+SEP in 2-month-old
Lacaune lambs (Fig. 3a). At week 12 after the prime, peripheral
blood mononuclear cells (PBMCs) were re-stimulated in vitro with
two pools of overlapping peptides covering the entire eGn
sequence (a N-ter and a C-ter peptide pool) in an IFNγ Enzyme-
Linked ImmunoSpot (ELISPOT) assay. Cultures with an irrelevant
peptide were used as controls (see Materials and methods
section). eGn-speciﬁc IFNγ responses were observed upon re-
stimulation with both the eGn N-ter and C-ter pool peptides in the
all-vaccinated groups versus the control sheep groups (Fig. 3b).
The most signiﬁcant difference of response versus the control
group was obtained with the cells from the pscDEC-eGn
vaccinated sheep (p < 0.01 with the N-ter pool and p= 0.05 with
the C-ter pool). The IFNγ spot number induced by the eGn N-ter
pool was signiﬁcantly higher with the PBMCs from the pscDEC-
eGn- than from the peGn vaccinated sheep (Fig. 3b). Although not
more expressed than peGn at the RNA level in sheep skin, pscDEC-
eGn appears more potent than pscCD11c-eGn and peGn to induce
IFNγ T-cell responses.
Fig. 1 Binding of anti-DEC205 mAb, anti-CD11c mAb, scCD11c-mCherry and scDEC-mCherry on sheep skin lymph DC subsets. a Sheep skin
lymph low-density cells were gated to select FSChi cells which were further separated as CD1b+ CADM1hi and CD1b+ CADM1lo cells,
corresponding mainly to cDC1s and cDC2s respectively. b The staining of the cDC1 and cDC2 subsets with the parental anti-DEC205 and anti-
CD11c mAbs is depicted (dark gray) compared to an isotype control (pale gray). c The staining of the cDC1 and cDC2 subsets with scDEC-
mCherry and scCD11c-mCherry is depicted (dark gray) compared to a scCtrl-mCherry (pale gray). The shown data are representative of two
independent experiments
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Fig. 2 Design and expression of peGn, pscDEC-eGn and pscCD11c-eGn. a Schematic representation of peGn, pscDEC-eGn and pscCD11c-eGn.
peGn includes the codon-optimized eGn sequence with its intrinsic signal peptide (SP, RVFV M segment from nt 411 to nt 1763) and cloned in
the pcDNA4-V5His expression vector. pscDEC-eGn and pscCD11c include the signal peptide (SP) of the VH chain of the parental mAb
sequence, the scFv (VH and VL) sequence and the nt 477 to nt 1763 portion of the codon-optimized eGn sequence. The VH and VL sequences
are connected together with a (G4S)4 linker and the scFv and eGn sequences are connected with a (G4S)3 linker. These chimeric sequences
were cloned in a pcDNA3.1 vector. b, c HEK293 cells were transfected with pcDNA3.1, peGn, pscDEC-eGn and pscCD11c-eGn. In (b), the cell
lysates (10 µl) were separated by SDS-PAGE under reducing conditions and eGn was revealed with anti-RVFV HMAF followed by a HRP-GAM
IgG. The predicted sizes of the expressed untargeted and chimeric eGn proteins are 48.8 kDa for untargeted eGn, 76.3 kDa for the scDEC-eGn
protein and 78.6 kDa for the scCD11c-eGn protein. All samples were gathered from the same experiment and were processed in parallel (1
repeated experiment). In (c) the cell lysates (100 µl) and the concentrated cell supernatants (500 µl) gathered from the same experiment were
spotted onto the same nitrocellulose membrane and the eGn protein was revealed as in (b) (1 repeated experiment). d Sheep skin lymph low-
density cells were reacted with the parental anti-DEC205, anti-CD11c or isotype control mAbs (top panel) or with the concentrated
supernatant from HEK293 cells transfected with peGn, pscDEC-eGn, pscCD11c-eGn and a negative control pcDNA3.1 (bottom panel). The
staining of the DAPIneg FSChi cells, which include dominantly cDCs, is depicted (dark gray) compared to control (dash line). Bound mAbs were
revealed with A488-DAM IgG and bound eGn with anti-RVFV HMAF followed by A488-DAM IgG. e Relative expression of peGn, pscDEC-eGn
and pscCD11c-eGn in sheep skin. peGn, pscDEC-eGn and pscCD11c-eGn (100 µg) were injected intradermally in 100 µl saline in inner front leg
sites of two sheep followed by SEP (532 V/cm). After 48 h, RNA was extracted from skin biopsies. eGn mRNA levels were measured using qRT-
PCR, normalized with RPS24 ribosomal RNA and expressed as 2−ΔCT values (1 repeated experiment). Absence of residual plasmid in the RNA
preparations was controlled using qPCR without reverse transcription
eGn-based DNA vaccine against RVFV in sheep
T Chrun et al.
4
npj Vaccines (2018)  14 Published in partnership with the Sealy Center for Vaccine Development
Immunization with peGn promotes the anti-eGn IgG responses in
sheep sera
Anti-eGn IgGs were measured in indirect enzyme-linked immu-
nosorbent assay (ELISA). The OD450 nm results from 1:100 diluted
sera are reported in Fig. 3c. Signiﬁcant detection of anti-eGn IgG
levels was obtained after one injection in the peGn and pscCD11c-
eGn-vaccinated group (p < 0.05 in comparisons versus week 0, Fig.
3c). The induction of signiﬁcant anti-eGn IgG levels was reached
for all groups after three inoculations (Fig. 3c). The levels of anti-
eGn IgG were higher in the sera from peGn- versus pscCD11c-eGn-
Fig. 3 IFNγ T-cell and Ab responses induced by peGn, pscDEC-eGn and pscCD11c-eGn in lambs. a Schematic representation of the
immunization protocol. The 2-month-old lambs were immunized at weeks 0, 4 and 8 with 400 µg of peGn, pscDEC-eGn, pscCD11c-eGn and
400 µg of pGM-CSF as adjuvant. Control lambs received pGM-CSF only. The plasmids were injected intradermally and the injection was
immediately followed by SEP (532 V/cm). Sera were collected and the IFNγ T-cell responses were assessed by ELISPOT at the indicated time
points. The syringe drawing is from Servier Medical Art which provides open source illustrations. b PBMCs (2.5 × 105) were plated in
Multiscreen plates coated with a capture anti-ovine IFNγ mAb (duplicated wells) and re-stimulated for 18 h with overlapping eGn peptides
covering the N- and C-terminal parts (5 µg/ml), or with an irrelevant peptide (5 µg/ml). IFNγ spot counts were considered eGn speciﬁc when
both duplicated well values from cells stimulated with eGn peptides were strictly superior to the duplicated well values from cells stimulated
with the irrelevant peptide. The mean spot numbers in stimulated wells minus the ones stimulated with irrelevant peptides are shown (net
mean values). Each symbol in the graphs represents an individual animal and the mean is indicated. P values between the two groups were
determined according to the Mann–Whitney test (*p < 0.05; **p < 0.01). c The serum of the lambs immunized with peGn, pscDEC-eGn,
pscCD11c-eGn and of control lambs were assayed for the detection of eGn-speciﬁc IgG using indirect ELISA. A lysate from HEK293 cells
transfected with peGn was used as coating (see Materials and methods section) and the individual sera were tested in a 1:100 dilution. The OD
signals at 450 nm from the sera collected at weeks 0, 4, 8 and 12 are shown in 3 C (1 repeated experiment). Each lamb serum is shown as a
distinct symbol and the mean OD value is represented as an horizontal bar. P values were determined using the two-way ANOVA with
Bonferroni’s correction to evaluate the statistical signiﬁcance of the OD value differences between vaccinated groups (*p < 0.05; **p < 0.01;
****p < 0.0001) and the signiﬁcance of the differences between the OD values measured at the different weeks versus at day 0 was evaluated
for each vaccinated group using paired t-test and the groups with statistically signiﬁcant differences are indicated by a box
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and pscDEC-eGn-vaccinated sheep at weeks 8 and 12, and they
tended to be higher in the pscDEC-eGn- than in the pscCD11c-
eGn-vaccinated sheep at week 12 (Fig. 3c). End-point titers were
calculated from serially diluted sera and gave similar differences
between groups (Supplementary material 3). The ELISA-positive
sera were tested for their capacity to neutralize RVFV in a
reduction plaque assay. None of the sera were neutralizing at the
difference with positive control sera from infected sheep (data not
shown). Overall, there was a graded capacity of our RVFV DNA
vaccines for induction of anti-eGn IgG, with peGn being the most
potent and pscCD11c-eGn being least potent, and the anti-eGn
IgGs were not capable of neutralizing RVFV in vitro.
peGn and to a lesser extent pscDEC-eGn induce partial protection
against infectious RVFV challenge in sheep
Sheep were challenged at week 12 with the RVFV 56/74 strain, a
previously demonstrated virulent strain in sheep.31 The infected
sheep were monitored for clinical symptoms and temperature,
and sera were collected regularly for viral RNA and infectious
particle detection (see Materials and methods). Two sheep died in
the control group at 6 and 8 days post challenge (dpc), and none
in the vaccinated groups (Table 1). The post-mortem lesions
included severe pulmonary edema, hemorrhages in multiple
organs, generalized lymphadenopathy and multifocal liver necro-
sis. The mean body temperature reached a peak over 41 °C in the
control, pscCD11c-eGn and pscDEC-eGn vaccinated groups (41.06,
41.23 and 41.33 °C respectively), whereas the mean body
temperature was signiﬁcantly reduced to 40.05 °C in the peGn
vaccinated sheep (p < 0.0001) (Fig. 4a). The total clinical score
(Table 1), reﬂecting the severity of the disease (see supplementary
material 2 for scoring), was the highest in the control group (92),
slightly reduced in the pscCD11c-eGn group (44) and much
decreased in the pscDEC-eGn (29) and peGn (22) vaccinated
group (Table 1). The main symptoms were nasal mucus
discharges, decreased activity, anorexia and conjunctive redness.
The viral RNA copies per ml serum were measured on 1, 2, 3, 4, 5,
6, 8 and 10 dpc for each sheep, except for the two dead sheep in
which copies were monitored up to 6 dpc (Fig. 4b). The mean
integrated value of the viral RNA copies per ml serum (viral RNA
area under the curve (AUC), see Materials and methods) reached
3.87 × 1012 in the control sheep and was signiﬁcantly decreased in
the pscDEC-eGn and peGn vaccinated sheep (6.39 × 1010, p < 0.05
and 4.41 × 109, p < 0.01 respectively, Fig. 4c). The viral RNA AUC
mean value of the pscCD11c-eGn group was slightly but not
signiﬁcantly reduced compared to the one of the control group
(3.89 × 1011). The peGn vaccinated sheep cleared the viral RNA
copies in serum on 6 dpc, the pscDEC-eGn vaccinated sheep on 8
dpc and the pscCD11c-eGn vaccinated and control group on 10
dpc. The particle-forming units (pfu) per ml serum were measured
over 8 days (Fig. 4d); the mean integrated values (pfu AUC, see
Materials and methods) were calculated and followed the same
trend as the viral RNA ones (Fig. 4e). The peGn vaccinated sheep
cleared the infectious particles in serum on 5 dpc, the pscDEC-eGn
vaccinated sheep and the pscCD11c-eGn vaccinated on 4 dpc and
control group on 8 dpc. Finally, the IgG responses directed to eGn,
to total RVFV antigens, and to N antigens and the neutralizing Abs
(NAbs) were monitored following infection (supplementary
material 4). The anti-eGn IgG response was boosted between 5
and 6 dpc in the vaccinated groups, reached the highest levels in
the peGn vaccinated sheep (p < 0.05), whereas the control sheep
developed detectable responses only from 10 dpc, reaching much
lower levels than in the vaccinated sheep. The anti-RVFV total
antigen IgG followed a similar trend. The titers of the NAbs at 10
dpc reached similar levels in all groups (supplementary material 4),
indicating that the DNA vaccines did not induce a clear priming of
NAbs, whereas they clearly primed the anti-eGn and anti-RVFV IgG
responses which were boosted by the viral challenge. Notably, in
agreement with an efﬁcient control of infection by the DNA
vaccines, the IgG response against the N immunodominant viral
protein, to which all sheep were naive at the time of challenge,
was lower in the vaccinated groups than in the control group (p <
0.05 at 10 dpc).
So far, our data show that peGn was efﬁcient at inducing
signiﬁcant levels of protective immunity, reducing by about 3
log10 the RNA viral loads and accelerating viral clearance, in
association with a strong decrease in the clinical symptoms
severity. pscDEC-eGn, which induced higher T-cell responses and
lower anti-eGn IgG responses than eGn, revealed to be less
protective than peGn, suggesting that the IFNγ T-cell response is
less critical than the Ab response in the protective immunity
induced by these vaccines. Finally, pscCD11c-eGn, which was the
least efﬁcient at triggering anti-eGn IgG responses, did not induce
signiﬁcant protection.
The anti-eGn IgG levels at challenge correlate with virological and
clinical protection
In order to get further insight into the immune parameter(s)
associated with protection against RVFV induced by our DNA
vaccines, we took advantage of the fact that the three DNA
vaccines induced a relatively wide range of values of immune,
virological and clinical parameters. These parameter values were
loaded in a principal component analysis (PCA) in order to identify
the main axes of the data variance as well as the key variables. In a
ﬁrst analysis where we used the data of the control and vaccinated
groups, the PC1 axis, which explains 36.82% of the variance,
clearly separates the data from the control and the vaccinated
group, with the peGn vaccinated group data being the most
distant from the control group data (Fig. 5a). In a second analysis
using the vaccinated group data, the PCA loading from each
parameter shows that the clinical scores, the viral RNA and the pfu
cluster together and oppose the anti-eGn and anti-RVFV IgG levels
at 0 dpc and less so at 6 and later dpc (Fig. 5b). The T-cell
responses, materialized by a short arrow, do not generate any
signiﬁcant pattern (Fig. 5c). Finally, we performed one to one
correlation analyses (Spearman's test) and found that the best
negative correlation index was obtained between the pfu AUC
and the anti-eGn IgG levels at 0 dpc (r=−0.6, p < 0.01, Fig. 5c and
supplementary material 5), and the correlation signiﬁcance was
lost at later time points. A similar negative correlation was
obtained between the clinical scores and the anti-eGn IgG levels.
No correlation could be found between the T-cell responses and
the virological or clinical parameters.
Altogether, the global analysis of the immune, virological and
clinical data of sheep vaccinated with peGn, pscDEC-eGn and
pscCD11c-eGn indicate that anti-eGn IgG levels at the time of
challenge are associated with protection and suggest that these
Table 1. Clinical scores upon infectious challenge in vaccinated lambs
Individual scoresa Total group
scoreb
Death per
group
Control 21,6,2,13,39,1,1,9 92 2/8
peGn 4,2,4,2,0,8,2,0 22 0/8
pscDEC-eGn 0,11,4,2,7,3,2,0 29 0/8
pscCD11c-eGn 3,8,6,5,5,7,8,1 43 0/8
aThe individual score was calculated by adding the daily clinical score over
20 days. The daily clinical score was established by monitoring anorexia,
eye aspect, activity/movement, lack of rumination, nasal mucus, prostra-
tion, respiratory movement, tremor (1 to 3 was attributed depending of
severity) and death (15 was arbitrarily attributed)
bThe total group score was calculated by adding the individual scores of
the group
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Abs, although not neutralizing in plaque assay, were instrumental
in the protective immunity induced by our DNA vaccines.
DISCUSSION
In this work, we showed that a DNA vaccine encoding untargeted
eGn conferred signiﬁcant protection against a RVFV challenge in
sheep. Our ﬁnding suggested that the anti-RVFV protective
immunity relied on antibodies, although not neutralizing, and
not on IFNγ-producing T cells. However, polyfunctional cytokine
secretion by T cells and cytotoxicity, which were not assessed
here, could also play a role. Importantly, our results indicate that
targeting antigens to DEC205 can be used to improve the T-cell
response in ruminants when this type of response would be
beneﬁcial.
The formalin-inactivated and live-attenuated vaccines have
been licensed in African countries where RVFV is endemic (see ref.
32 for recent review on RVFV vaccines). However, inactivated
vaccines require a booster and annual revaccinations, the live-
attenuated Smithburn vaccine is teratogenic and the live-
attenuated clone 13, which has a higher safety proﬁle associated
to a large deletion in the small segment, can nevertheless induce
abortion during the ﬁrst trimester of gestation.33 With the goal to
improve safety, next-generation live-attenuated vaccines, such as
a reassortant between clone 13 and the MP-12 chemically
attenuated strain34 or MP-12-derived clone with silent muta-
tions,35 have been developed. However, there is resistance of
many countries to authorize live-attenuated vaccines, due to the
risk of reversion to virulence. Therefore, other vaccine candidates
were generated and demonstrated promising results in sheep and
include subunit vaccines,36,37 virus-like particles,36 virus replicon
particle vaccines,34 virus-vectored vaccines36,38,39 and DNA.40 In
contrast to our results, a DNA vaccine encoding for the
glycoprotein precursor Nsm/Gc/Gn did not induce T- or B-cell
response in sheep, using 3 injections of 400 µg DNA in lipofectin
as a delivery method.40 Several of these novel candidates were
compared to a commercial vaccine, either to an inactivated
vaccine36 or to clone 13.34 In the ﬁrst study, the inactivated
Fig. 4 Body temperature and viremia upon RVFV challenge in lambs vaccinated with peGn, pscDEC-eGn and pscCD11c-eGn. The vaccinated
and control sheep were challenged with the RVFV 56/74 strain (106 TCID50) 3 weeks after the last immunization. a The rectal temperature was
measured daily. Data are mean ± SD of individual values (n= 8 sheep per experimental group). The p values were determined according to a
two-way ANOVA test with Bonferroni’s correction (****p < 0.0001). b The viral RNA copy numbers/ml in serum were quantiﬁed by qRT-PCR and
the mean values for each group with the top standard error of mean are shown over times. c The viral RNA area under the curve (viral RNA
AUC) was calculated over 10 days for each animal. d The plaque-forming unit load (pfu/ml) were quantiﬁed in viral RNA-positive sera and the
mean values for each group with the top standard error of mean are shown over times. e The pfu area under the curve (pfu AUC) was
calculated over 8 days. Each symbol represents an individual animal and the mean is indicated by a horizontal line (n= 8 per experimental
group). In (b–d), the p values between the vaccinated and control groups were determined with the Mann–Whitney test (*p < 0.05; **p < 0.01;
***p < 0.001). A cross symbol indicates death
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vaccine decreased by 4 log10 the peak of viral RNA levels in serum
and was less efﬁcient than puriﬁed eGn in oil-in-water adjuvant or
than a viral replicon encoding for Gn/Gc.36 In the second study,
clone 13 and the viral replicon induced full protection without
detectable viral RNA in serum.34 However, it should be pointed out
that the mean RNA copies per ml serum at the peak of infection of
control sheep was close to 8 log10 copies in the ﬁrst study36 and
to 10 log10 copies in the second one,34 whereas it was above 12
log10 copies in our study, suggesting that our challenge
conditions were more severe. We can speculate that a milder
challenge would have improved the reduction of viral RNA load
induced by our DNA vaccine (about 3 log10 here). Nevertheless,
caution should be taken to compare these studies which were
performed with different sheep breeds and different viral strains.
Therefore, efforts should be made to better standardize across
labs challenge experiments that should include a commercial
vaccine as a reference to identify promising vaccines.
Higher levels of anti-eGn IgG were reached with peGn than with
pscDEC-eGn and pscCD11c-eGn and correlated to protection. The
higher Ab quantity could result from a higher expression of peGn
in vivo, a hypothesis which is supported by the tendency for
higher mRNA expression from peGn in skin; however, an analysis
of protein expression from a large number of transfected skin
biopsies would be necessary to further validate this hypothesis. In
addition, untargeted eGn may be available to B cells for a longer
time than the DC-targeted eGn fusions which are likely to be
rapidly secreted and readily internalized by the targeted receptor,
a feature which has been proposed to reduce Ab responses while
promoting T-cell responses.15
Besides quantity, the quality of the antibodies generated by our
different DNA vaccines may also play a role in protection. In that
respect, the fact that the anti-eGn antibodies induced by all three
DNA vaccines were not neutralizing in vitro is puzzling. In addition,
our DNA vaccines did not appear to prime for neutralizing
antibody production since the DNA vaccinated sheep and control
sheep showed similar levels at 10 dpc. In contrast, soluble eGn
produced by drosophila cells and delivered in a oil-in-water
adjuvant could induce neutralizing antibodies in sheep36 but in
line with our ﬁnding, a DNA vaccine encoding untargeted eGn
administered to mice using gene gun in skin conferred signiﬁcant
protection with weak induction of neutralizing antibodies.6 The
eGn protein, related to its mode of expression by skin cells, may
not be in an optimal conformation to induce neutralizing
antibodies. Alternatively, the capacity of antibodies to neutralize
the infectivity of RVFV may be different in the gold standard assay
using VeroE6 cells and in the in vivo conditions, due to the likely
difference of viral receptor engagement, as proposed in the case
of ﬂaviviruses.41 The anti-eGn antibodies induced by DNA vaccines
may display anti-RVFV properties such as complement-dependent
inhibition or Ab-dependent cellular cytotoxicity (ADCC) or
Fig. 5 PCA and correlation analysis of the clinical, virological and immune response data of the lambs vaccinated with peGn, pscDEC-eGn and
pscCD11c-eGn. a A PCA plot of the clinical, virological and immune response data (=PCA variables) of vaccinated and non-vaccinated sheep is
depicted, with each sheep represented as a dot in a speciﬁc color according to its group assignment: PC1 explains 36.82% of the total
variation of the data between sheep and PC2 explained a further 18.21% of the variation. The vaccination regimen is indicated by a distinct
color (red for peGn, blue for pscDEC-eGn, green for pscCD11c-eGn). b Thirty-one individual input variables were loaded (see Materials and
methods) and the most relevant ones are indicated on the ﬁgure for clarity: viral RNA AUC, pfu AUC, individual clinical scores, integrated
temperature measurements, T-cell responses at week 12, anti-eGn IgG OD signals (AbeGn) at 0, 5, 6 and 10 dpc, anti-N IgG OD signals (AbN) at
8 and 10 dpc, NAb titers (NAb) at 10 dpc and anti-RVFV IgG OD signals (AbRVFV) at 0, 5, 6 and 10 dpc. c Correlation analyses between the
immune response data versus the clinical and virological data. For each vaccinated lamb, the anti-eGn and anti-RVFV IgG OD signals at 0, 5
and 6 dpc, the NAb titers at 10 dpc and the anti-N IgG OD signals at 5, 6 and 10 dpc were subjected to bilateral Spearman's correlation analysis
against the individual clinical scores, the viral RNA AUC and the pfu AUC data. The statistically signiﬁcant negative correlations are indicated in
red (*p < 0.05; **p < 0.01) and the r coefﬁcient is indicated
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phagocytosis. The ADCC efﬁcacy depends on the Ab isotype and
on the nature of the recognized epitope on the viral protein, as
shown in the case of inﬂuenza.42 Untargeted eGn and eGn fused
with scFv may differ in their respective capacities to generate such
anti-viral antibodies. Assessment of the anti-RVFV Ab functions will
require the development of suitable in vitro tests which would
help to potentially identify better correlates of protection than
anti-eGn Ab levels.
pscDEC-eGn did promote the IFNγ T-cell responses in sheep,
although it tended to be less expressed than peGn in sheep skin.
In the context of DNA vaccination, DEC205 targeting appeared to
have a positive effect on T-cell responses in several instances such
as in mice12,13 and even cattle,43 but in other cases DEC205
targeting rather decreased the IFNγ-producing T-cell response
with regulatory T-cell induction.44,45 Here, the targeting of eGn to
CD11c did not promote T-cell responses, although pscCD11c-eGn
was at least as expressed as pscDEC-eGn. This is in contrast with
results in mice where CD11c targeting strongly enhanced the IFNγ
T-cell responses.14 Therefore, the outcome of DEC205 and CD11c
targeting of antigens expressed by DNA plasmids is inconsistent
and difﬁcult to predict for T-cell as well as for B-cell responses,12,44
in a given species and throughout species, and could depend on
several parameters. Firstly, DC activation by the DNA delivery
method is a prerequisite to induce strong T-cell responses, as the
targeting of steady-state DC induce regulatory T cells and
tolerance;46 therefore, the DNA delivery method, the combination
with adjuvants and the duration of plasmid expression could all
affect the efﬁcacy of DC targeting. In the present work, we
combined electroporation which has been proposed to have a
strong adjuvant effect through inﬂammatory cytokine release and
APC mobilization in skin,29 with a plasmid encoding ovine GM-
CSF, a largely used cytokine adjuvant in DNA vaccination including
in sheep.8,28 Secondly, the nature of the targeted vaccine antigen,
by its content in self-mimicking epitopes expanding regulatory T-
cell responses, may affect effector T-cell priming.47 Thirdly, the
same targeted orthologous receptor may have different sub-
cellular routing pathways with variable kinetics in different
species, impacting on the efﬁcacy of major histocompatibility
complex (MHC) class I or class II antigen presentation,17,48 and
even in the same species, Ab targeted to different epitopes on the
same molecule were shown to induce different responses.49
Finally, the distribution of expression of the targeted receptor
among cell types and mononuclear phagocyte subsets in different
species may affect the immune response, given the functional
specialization of the different subsets. Indeed, in humans and
ruminants, DEC205 expression on leukocyte populations is much
broader than in mice and is found on B, T and NK lympho-
cytes.50,51 In mice, CD11c is expressed primarily on DCs and also
on some macrophages and natural killer (NK) cells, whereas in
sheep CD11c is widely expressed on macrophages and B cells.52
To the best of our knowledge, our study is the ﬁrst to
demonstrate that a plasmid encoding for eGn induces a signiﬁcant
protection in sheep, indicating that an effective vaccine against
RVFV could be produced based on DNA. However, our strategy
needs to be further optimized. Indeed, for application in the ﬁeld
and especially in Africa, the minimum number of administrations
and the plasmid dose to achieve protection should be established
with downscaling experiments, and the mode of delivery should
be adapted to mass vaccination, such as with a high pressure
needle-free delivery system which has been shown to be as
efﬁcient as electroporation in pigs16 or possibly with new portable
electroporation-based systems.53 The level of protection that we
achieved is incomplete and complete immunity is desirable to
protect the highly sensitive fetuses; however, a strong decrease in
viral load would also decrease the risk of transmission to mosquito
vectors. The immunity triggered by peGn might be further
improved by adding other RVFV antigens such as by adding Gc
(or eGc) and/or N proteins. While the T-cell response against eGn
did not seem to impact protection, T-cell responses against other
RVFV antigens may be of value. Better vectors driving higher
antigen expression would be also desirable: indeed, differences in
expression between vectors, as suggested by Fig. 2e, may have
masked a positive effect of the targeting. Finally, as our results
support the importance of anti-eGn IgG in protection, strategies to
further improve this type of response should be privileged. In that
respect, eGn could be targeted to receptors such as CLEC9A which
is a particularly suitable targets for Ab response induction.54,55
CLEC9A is selectively expressed on cDC1s in different species
including in sheep,23 and its targeting results in the prolonged
antigen presentation favoring follicular helper T-cell development,
strong germinal center formation, leading to high Ab responses of
strong afﬁnity.54 However, despite the existence of a CLEC9A
ortholog in sheep and high expression of mRNA by cDC1s,23 we
were unable to generate any anti-CLEC9A mAb reacting with
sheep cDC1s. Alternatively, XCR1 targeting, another receptor
exclusively expressed by cDC1s across species, could also be used
to successfully induce high anti-eGn IgG responses in sheep, as
recently showed by us in pigs for promoting anti-inﬂuenza M2e
IgG responses.56
In conclusion, we showed that DNA vaccination is a very
promising control strategy against RVFV in sheep. In addition, by
using CD11c and DEC205 targeting which was detrimental to
protection, we found that Ab responses against eGn, and not IFNγ
T-cell responses, are signiﬁcant correlates of protection in sheep.
This outcome of DC targeting related to its capacity to modulate
immune responses could be extended to other pathogens for
identifying immune correlates of protection in application species
where mechanisms are difﬁcult to investigate. In the case of RVFV,
this DC-targeting strategy guides us towards the development of
future vaccines optimized for induction of high levels of anti-eGn
IgG whose anti-viral functions remain to be deciphered.
MATERIALS AND METHODS
Abs and hydridomas
The hybridomas producing the anti-ovine CD11c (mouse IgG1, OM1) and
the anti-ruminant DEC205 (mouse IgG2b, CC98) mAbs were developed by
INRA and the Pirbright Institute (former Institute for Animal Health
(Compton, UK)) respectively. The mAbs used in this study are the anti-
CD1b (mouse IgG2a, Th97, WSU (USA)), the anti-CADM1 (chicken IgY, 3E1,
CliniScience, #CM004-3), the anti-bovine IFNγ (CC330, Bio-Rad, #MCA2112)
and the biotinylated (biot)-anti-bovine IFNγ (CC302, Bio-Rad, catalog
#MCA1783). The conjugated antibodies are the Alexa 647-conjugated
(A647)-donkey anti-chicken IgY (Jackson ImmunoResearch, #703-606-155)
and the A488-donkey anti-mouse IgG (DAM) (Jackson ImmunoResearch,
#715-546-150), the A488-goat anti-mouse (GAM) IgG2a (Fisher Scientiﬁc,
#10114282), the phycoerythrin (PE)-GAM IgG1 (Fisher Scientiﬁc,
#10246642) and PE-GAM IgG2b (Fisher Scientiﬁc, #10012802), and the
horseradish peroxidase (HRP)-rabbit anti-mouse IgG (Sigma-Aldrich,
#A9044) and HRP-mouse anti-sheep IgG (Sigma-Aldrich, #A9452). The
anti-RVFV HMAF production was approved by the French Ministère de la
Recherche et de l’Enseignement Supérieur under the number 02518.2 and
was conducted at ANSES, Lyon, France. Balb/c mice were inoculated
intraperitoneally with inactivated RVFV-infected mouse brain suspension in
Freund’s complete adjuvant on days 0 and 1, in Freund’s incomplete
adjuvant on days 7 and 14, and with a virulent suspension in Freund’s
incomplete adjuvant on days 21 and 28. On day 25, the mice were
inoculated intraperitoneally with TG180 sarcoma cells. After 1 week, ascitic
ﬂuid was harvested.
Cell lines
Human embryonic kidney cells (HEK293, ATCC® CRL-1573) and African
green monkey kidney cells (VeroE6, provided from Pierre Russo, Anses,
Sophia-Antipolis Laboratory, Ruminant Pathology Unit, 06902, France)
were maintained in culture with Dulbecco’s modiﬁed Eagle's medium
(DMEM, Life Technologies), supplemented with 5% decomplemented fetal
bovine serum (FBS) and antibiotic solution at 37 °C. Cell lines were checked
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to be free of mycoplasma contamination using a mycoplasma detection Kit
(MycoAlert™, Lonza, Switzerland).
RVFV strains
The virulent strain RVFV 56/74, provided by Alejandro Brun (CISA-INIA),
originally isolated from an infected cow,31 was ampliﬁed on C6/36 insect
cells and titrated on VeroE6 cells according to the Reed–Muench method.
The attenuated RVFV virus MP-12 strain,57 provided by Michèle Bouloy
(Paris Pasteur Institute), was ampliﬁed and titrated on VeroE6 cells.
Construction and production of plasmids
Genes encoding for the variable region of the murine heavy (VH) and light
(VL) chains of the anti-ruminant DEC205 and the anti-ovine CD11c mAb
were ampliﬁed by PCR and subcloned in the pSK vector for sequencing
(Synogene). The sequences were deposited on Bankit (https://www.ncbi.
nlm.nih.gov) under the ID 2070859 (release on 1 September 2018). For
each mAb, the original VH signal peptide was fused to the VH and the VL
fragments joined by a sequence encoding for a ﬂexible linker (G4S)4 to
generate the scFv sequences. A sequence encoding for the ectodomain of
the Gn glycoprotein (eGn) of the ZH501 strain was codon-optimized for
expression in eukaryotic cells (Genecust, Luxembourg) and was fused in
frame to the carboxy terminus of the scFv sequence with a (G4S)3 linker.
The eGn sequence spans from nucleotide (nt) 477 to nt 1763 (DQ380202.1)
of the RVFV M segment, and is devoid of transmembrane domains. The
fusion constructs encompassing the VH signal peptide, scFv and eGn were
cloned into a pcDNA3.1 expression vector (InvitroGen) and the resulting
plasmids are designated as pscDEC-eGn and pscCD11c-eGn. In addition,
fusion constructs with mCherry replacing eGn sequences were built as well
as a construct including a control scFv, provided by Synogene (pscDEC-
mCherry, pscCD11c-mCherry and pscCtrl-mCherry). A plasmid encoding for
untargeted eGn was generated (peGn). peGn includes the nt 411 to nt
1763 codon-optimized sequence of the M segment with the natural signal
peptide of Gn58 cloned into a pcDNA4-V5His expression vector (InvitroGen)
(Genecust). The plasmid encoding for ovine GM-CSF (pGM-CSF) has been
previously described.28 A ﬁreﬂy luciferase expression plasmid (pLuc) was
kindly provided by Stéphane Biacchesi (INRA, France). The sequence
encoding the RVFV N nucleoprotein was cloned into the expression vector
pMT/BiP/SNAP-His. Plasmid productions for immunization were prepared
using Endofree® Plasmid Giga Kits (Macherey-Nagel) and were stored at
−20 °C until use.
Plasmid transfection in vitro
HEK293 cells (5 × 106 cells) were transiently transfected with JetPRIME®
(Polyplus, USA) according to the manufacturer’s protocol. Brieﬂy, 10 µg of
peGn, pscDEC-eGn, pscCD11c-eGn or pcDNA3.1 (negative control) were
mixed with 20 µl of polymer reagent and added to the cells. The
supernatants and cells were harvested at 72 h post transfection.
Cell lysate and supernatant preparation
Cell pellets of transfected HEK293 cells or MP-12-infected VeroE6 cells were
lysed in borate lysis buffer (1% Triton X-100, 50 mM borate, 150mM NaCl,
pH 9)+protease inhibitors at a 1:9 volume ratio (pellet/buffer), the lysates
were sonicated, aliquoted and kept frozen. The transfected cell super-
natants were concentrated 20 to 40 times with Amicon® Ultra centrifugal
ﬁlter 30 K (Millipore) and a protease inhibitor cocktail was added.
Western blots and dot blots
Cell lysates were analyzed by western blot following a 12% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) under
reducing conditions and cell supernatants were analyzed by dot blot
under nonreducing conditions. Blots were incubated overnight at 4 °C with
anti-RVFV HMAF in a 1:1000 dilution in phosphate-buffered saline (PBS)
+10% fat-free milk (w/v) followed by HRP-rabbit anti-mouse IgG Ab.
Immunoreactive bands were visualized with ECL substrate (SuperSignal™
West Femto, Thermoﬁsher) and dots were visualized with 3,3′-diamino-
benzidine substrate (Sigma-Aldrich). Image acquisitions were done with
Chemidoc imaging system (Bio-Rad). The blot experiment was performed
with respect to the ethical guidelines and the technical protocols
conducted at ANSES laboratory in Lyon, France.
Lymph duct cannulation and low-density lymph cell collection
The prescapular lymph duct of Prealpes sheep was cannulated to collect
pseudo-afferent lymph cells draining from the skin, as previously
described.59 The cannulated sheep were housed at the Unité Commune
d’Expérimentation Animale in Jouy-en-Josas, France. This protocol was
done under compliance with national legislation on animal experimenta-
tion and was approved by the Committee on the Ethics of Animal
Experiments of the INRA research center in Jouy-en-Josas (COMETHEA)
under the number 11–019.
Assessment of plasmid transfection efﬁcacy in sheep skin
Plasmid administration in sheep skin was performed on Prealpes sheep (2
to 12 months old) under general anesthesia (2 mg/kg xylazine and 10mg/
kg ketamine, intramuscular route). Immediately after intradermal injection
of DNA in the left and right inner front leg zones, SEP was performed on
the site of injection using the CUY 21 EDIT system (BEX, Tokyo, Japan). Disk
electrodes (10mm) were loaded with conductive gel (Alcyon, France) and
6 electric pulses were applied during 10ms with 90ms interval. In order to
evaluate the V/cm parameter leading to optimal transfection in sheep skin,
a pLuc reporter vector (100 µg) was injected intradermally and the injected
skin areas were subjected to SEP with escalating pulses from 0 to 1331 V/
cm. After 2 days, skin punch biopsies were harvested and lysed with 150 µl
of lysis reagent (Luciferase Assay System E1500, Promega). Biolumines-
cence was measured using the In Vivo Imaging System (IVIS-200, Xenogen,
UK) after adding 100 µl luciferine substrate. The optimal V/cm was found to
be 532 V/cm and was used in all subsequent experiments (supplementary
material 1). This experiment was approved by the COMETHEA ethic
committee under the number 201504211534406 (APAFIS#520) in accor-
dance with national guidelines on animal use and performed at the Unité
Commune d’Expérimentation Animale UCEA-INRA in Bressonvilliers, France.
In order to compare the expression of the different vaccine plasmids in
sheep skin in vivo, plasmids (100 µg) were injected intradermally and
subjected to SEP (532 V/cm). After 2 days, sheep were killed, 4 skin biopsies
were collected from each injection site and frozen in liquid nitrogen. This
experiment was approved by the French ethical committee CEEA Val de
Loire, received the authorization number 04150.02 in accordance with
national guidelines on animal use and was conducted at the Plate-Forme
d’Infectiologie Expérimentale PFIE-INRA, Nouzilly, France.
Immunizations and RVFV challenge
The experiment was approved by the Spanish ethical committee
Department Medi Ambient i Habitatge de la Generalitat de Catalunya
CE-8820 and was conducted at IRTA-CReSA, Barcelona, Spain, under
compliance to Spanish biosafety and ethic rules. Lambs (2 months old)
were equally distributed in both sexes and were housed in the IRTA-CReSA
experimental farm in Lerida, Spain, under A-BSL1. Lambs were randomly
divided into 4 groups of 8 lambs and the vaccination was performed 3
times at 4 week intervals (0, 4, 8) under general anesthesia (2 mg/kg zoletil,
intramuscular route); 8 animals per group is classically used in vaccine
studies. Then, 400 µg of peGn, pscDEC-eGn or pscCD11c-eGn were injected
intradermally together with 400 µg of plasmid adjuvant (pGM-CSF),
followed by SEP as described above. A non-vaccinated control group
(PBS plus pGM-CSF) was included. Sera were collected at weeks 0, 4, 8 and
12 post immunization and PBMCs were harvested at week 12 to analyze
the T-cell response. The immunized sheep were moved to a A-BSL3 to
perform the challenge at day 91 after the ﬁrst immunization with 106
TCID50 of the RVFV 56/74 strain in 2 ml volume by subcutaneous route.
After challenge, the clinical signs were daily monitored in a blinded
manner. The daily clinical score per sheep was established by monitoring
anorexia, eye aspect, gait, lack of rumination, mucosa aspect, prostration,
respiratory movement, tremor (1 to 3 depending of severity) and death
(15) (supplementary material 2). An individual clinical score per sheep was
obtained by adding the daily values over 20 days. The ﬁnal global score per
group was the addition of each individual score. Serum was collected at 0,
1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20 dpc. At the end of the study, the
animals were killed by an overdose of sodium pentothal.
Low-density lymph cells and PBMC isolation
Low-density lymph cells were enriched over an optiprep gradient as
previously described by our group,59 frozen in FCS+10% DMSO using a
Nalgene Mr. Frosty Cryo 1 °C Freezing Container and kept in liquid
nitrogen. PBMCs were isolated in the A-BSL3 IRTA-CReSA’s facility using
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8ml Vacutainer® CPT™ (BD Bioscience) by centrifugation at 1800 × g for
35min at 25 °C. Tubes were shipped overnight at 4 °C to INRA, Jouy-en-
Josas, France. Upon arrival, PBMCs were washed with PBS+1.3 mM citrate
and re-suspended in X-vivo medium (Ozyme, France) supplemented with
50% FBS for overnight recovery at 4 °C.
Staining of lymph dendritic cell and ﬂow cytometry analysis
Low-density lymph cells were thawed and incubated on ice with PBS
supplemented with 4% horse serum for 30min. To analyze DEC205 and
CD11c expression on DC subsets, lymph cells were labeled with a mix of
primary mAbs (2 µg/ml) for 30min, being either anti-CD1b+anti-CADM1
+anti-DEC205 mAbs, or anti-CD1b+anti-CADM1+anti-CD11c mAbs.
Appropriate isotype control mAbs were used. Cells were washed and
ﬁnally incubated with a mix of secondary Abs (1:200) being respectively
A488-GAM IgG2a+A647-anti-chicken IgY+PE-GAM IgG2b or A488-GAM
IgG2a+A647-anti-chicken IgY+PE-GAM IgG1. To analyze the binding of
scDEC-mCherry and scCD11c-mCherry, the fusion proteins (50 µg/ml)
+anti-CD1b+anti-CADM1 mAbs were incubated with lymph cells on ice
for 30min. A scCtrl-mCherry provided by Synogene was used as control.
Cells were washed and incubated with PE-GAM IgG1+A488-GAM IgG2a. To
analyze the binding of scDEC-eGn and scCD11c-eGn on low-density lymph
cells, the concentrated supernatants of HEK293 transfected cells with
peGn, pscDEC-eGn, pscCD11c-eGn and pcDNA3.1 (negative control) were
incubated with cells for 2 h at 4 °C. Cells were then incubated with anti-
RVFV HMAF (1:1000) and ﬁnally with A488-DAM IgG (1:200). Dead cells
were excluded by 4',6-diamidino-2-phenylindole (DAPI) staining. Flow
cytometry acquisitions were done with a LSR Fortessa ﬂow cytometer
(Becton Dickinson) and results were analyzed using FlowJo 10.0.6 software.
Evaluation of eGn-speciﬁc T-cell responses by ELISPOT
IFNγ-secreting T cells were detected using polyvinylidene diﬂuoride
membrane-bottomed 96-well plates (Multiscreen®HTS, Millipore) coated
with 15 µg/ml anti-bovine IFNγ (capture mAb) in PBS. PBMCs (2.5 × 105)
were added to wells and re-stimulated with 5 µg/ml overlapping peptides
(20mers, offset 8, Mimotopes, Australia) covering the N-terminal (AEDPHL
[…] LLPDSF) and C-terminal (VCFEHK […] NYQCHT) amino-acid sequence
of the eGn protein in X-vivo medium (Ozyme, France) supplemented with
2% FBS and antibiotic solution at 37 °C for 18 h. The overlapping peptides
were divided in 2 pools initially diluted in H2O/acetonitril (5 mg/ml) and
distributed in 5 µl per well to have 1 µg of each peptide per well and avoid
any toxicity of the H2O/acetonitril diluent. In addition, cells incubated with
5 µl of H2O/acetonitril peptide diluent (1:1 volume) and with an irrelevant
peptide derived from the HIV polymerase (IKDFHVYFRESRDALWKGPG)
were used as negative controls. Cells cultured with ConA (25 µg/ml) were
used as positive controls. Each condition was tested in duplicated wells.
IFNγ-secreting T cells were revealed using biot-anti-bovine IFNγ mAb at
0.5 µg/ml followed by alkaline phosphatase-conjugated streptavidin
(Mabtech, Sweden) and BCIP/NBT reagent (Life Technologies). Plates were
automatically counted using the iSPOT AID ELISPOT reader. IFNγ spot
counts were considered eGn speciﬁc when both duplicated well counts
from cells stimulated with eGn peptides were strictly superior to the
duplicated well counts from cells stimulated with irrelevant peptide. The
net mean of the IFNγ spot counts were obtained by subtracting the mean
counts from wells stimulated with irrelevant peptides out of the mean
counts from wells stimulated with eGn peptides.
Evaluation of anti-eGn, anti-N and anti-RVFV responses by ELISA
High-binding 96-well plates Nunc MaxisorpTM (ThermoFisher) were coated
overnight at 4 °C either with 100 µl lysates from MP-12-infected VeroE6
cells or from HEK293 cells transfected with peGn or with SNAP-tag puriﬁed
N protein, which was produced using a Drosophila expression system and
kindly provided by Philippe Despres (Paris Pasteur Institute, France). The
same lysates and protein batch was used in all experiments. The same
positive and negative sheep sera were used to validate each plate. Sera
were diluted 1:100 in PBS+2% fat-free milk (w/v) and incubated on the
coated plates at 37 °C for 1 h. The plates were subsequently incubated with
HRP-mouse anti-sheep IgG in a 1:4000 dilution at 37 °C for 1 h. HRP
enzymatic activity was revealed using TMB (3,3′,5,5′-tetramethylbenzidine)
substrate. Optical density was measured at 450 nm using a TECAN
microplate reader. Corrected OD values were obtained by subtracting the
signal of wells coated with lysates from uninfected VeroE6 cells, from
HEK293 cell transfected with pcDNA3.1, or coated with SNAP-tag. To
calculate anti-eGn IgG end-point titers, 1:100 diluted sera were serially
diluted 1:1 and the ELISA was processed as described above. End-point
titers were calculated with a regression analysis plotting dilution versus
A450 as the highest dilution giving twice the absorbance of the mean of
negative control wells.
RNA extraction from serum and transfected skin samples
Total RNA was extracted from post-infection sera with QIAMP kit (Qiagen)
according to the manufacturer’s instructions and eluted in 60 µl RNase-free
water using QIACube (Qiagen). Total RNA was extracted from skin biopsies
collected from the inoculation sites (about 250mg per site) using 10ml
TRIzol LS reagent (Thermo Fisher Scientiﬁc) and homogenization with
Ultra-Turrax T8. The ﬁrst RNA extract was puriﬁed using a RNeasy MinElute
cleanup column. The 1 µg puriﬁed RNA was treated twice with 5 µl of
RNAse-free DNAse (30 Kunitz units, Qiagen) in order to remove any
residual DNA plasmid from the injection and subjected to a ﬁnal
puriﬁcation on column.
Gn RNA quantiﬁcation by qRT-PCR
For quantiﬁcation of viral RNA copies per ml sera, a one-step qRT-PCR was
performed using the SuperScript III Platinum One-Step qRT-PCR kit
(Invitrogen) as previously described.60 Primers were designed to amplify
a nt 1164 to nt 1258 Gn sequence of the M segment: forward primer 5′-
AAA GGA ACA ATG GAC TCT GGT CA–3′, reverse primer 5′- CAC TTC TTA
CTA CCA TGT CCT CCA AT-3′. A ﬂuorescent probe was designed that
hybridizes to the speciﬁc PCR product: FAM 5′- AAA GCT TTG ATA TCT CTC
AGT GCC CCA A-3′ TAMRA. A standard corresponding to nt 1135 to nt 1286
of the M segment was synthetized using the Riboprobe® In Vitro
Transcription Systems (Promega). The qRT-PCR was done on 3 µl of the
serum elution and the program was 45 °C for 30min, 95 °C for 5 min, linked
to 45 ampliﬁcation cycles of 95 °C for 5 s and 57 °C for 35 s, and cooling at
37 °C for 30 s. TaqMan run of experimental samples contained at least two
replicates, a known positive control (RVFV ZH501 strain), a negative control
(an other Phlebovirus RNA) and nuclease-free water. The number of viral
RNA copies/ml in each serum sample was determined using the Gn RNA
standard calibration curve. For each animal, the AUC of the viral RNA
copies per ml over 10 days (viral RNA AUC) was calculated. For the
detection of Gn mRNA in transfected skin biopsies, a two-step qRT-PCR
was performed. The reverse transcription was done using the TaqMan®
Reverse Transcription Reagents (Applied Biosystems). In order to check
that the transfected skin RNA did not include detectable residual plasmids,
reverse-transcribed (3 ng estimated cDNA) and non-reverse transcribed
RNA (3 ng RNA) were subjected to PCR reaction with the iTaq UniverSYBR
Green (Bio-Rad) for amplifying a Gn fragment with forward primer 5′ – AGT
GCG ATG GGC AGT TGT C–3′ (M segment, codon-optimized sequence) and
reverse primer 5′ – TTC TTG AAC ACG GCA AAT GG–3′. The PCR cycling
conditions were 95 °C for 10min, linked to 40 cycles of 95 °C for 15 s and
60 °C for 1 min. No residual plasmid could be detected in any of the RNA
samples. The relative expression of Gn mRNA in transfected skin samples
was normalized using the qRT-PCR signals obtained with the ovine
ribosomal protein 24 (RSP24) gene which is a stably expressed reference
gene in sheep cells.61
Virus titration by plaque assay
The sheep sera were serially diluted in DMEM medium and inoculated onto
VeroE6 cells in 12-well plates for a plaque assay over 5 days. The pfu were
revealed by 1% (w/v) violet crystal and counted. For each animal, the
integrated pfu load corresponding to the AUC of the number of pfu per ml
serum over 8 days was calculated (pfu AUC).
Plaque reduction assay
Neutralizing antibody was measured using plaque reduction and
neutralization test. Sera were diluted 1:10 to 1:104 in DMEM and incubated
with 100 pfu of MP-12 virus at 37 °C for 1 h to enable neutralization to
occur. Next, the virus and the serum mix (500 μl) were added to VeroE6 cell
monolayers for a plaque assay. The neutralizing antibody titers were
established as the last dilution which inhibited 50% of the foci number per
well compared to virus-only control titration.
Statistical and correlation analysis
Data were analyzed with the GraphPad Prism 6.0 software. To compare the
T-cell responses, the anti-eGn IgG titers, the NAb titers at day 10, the viral
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RNA at day 3, the pfu at day 2, the viral RNA AUC, the pfu AUC values and
the luciferase signals between the two groups, we used the unpaired non-
parametric Mann–Whitney test, as the data did not pass the normality test
(Kolmogorov–Smirnov test). The paired parametric t-test was used to
compare the antibody responses at different time points versus at day 0
within the same group. A two-way analysis of variance (ANOVA) test
followed by Bonferroni’s correction was used to compare the OD values of
the Ab responses and the body temperature between immunized groups
each day after infection, as the data distribution passed normality test. In
most cases the standard deviations of the data were statistically similar
between vaccinated groups (Brown–Forsythe test) but they were different
between the vaccinated and the non-vaccinated groups. The correlation
analysis between the immune response data versus the individual clinical
scores, the viral RNA AUC and the pfu AUC was done with the bilateral
Spearman's non-parametric test. The PCA was done with 31 factors and
included the individual viral RNA copies/ml at 2, 3, 4, 5 and 6 dpc, the viral
RNA AUC, the individual pfu/ml at 2, 3 and 4 dpc, the pfu AUC, the
individual clinical scores, the integrated temperature measurements, the T-
cell responses at week 12, the anti-eGn IgG OD signals at 0, 5, 6, 8, 10 and
12 dpc, the anti-N IgG OD signals at 5, 6, 8, 10 and12 dpc, the anti-RVFV IgG
OD signals at 0, 5, 6, 8, 10 and 12 dpc and the NAb titers at 10 dpc. PCA
graphics has been produced using FactoMineR R package (http://
factominer.free.fr/).
Data availability
All datasets and tools developed by the authors are available to readers.
Samples for RVFV-infected sheep and vaccinated sheep will require legal
authorization from the Agence Nationale de la Sécurité du Médicament
(ANSM), as RVFV is a “select agent” in this country. The ScFv sequences
were deposited on Bankit (https://www.ncbi.nlm.nih.gov) under the ID
2070859 (release on 1 September 2018).
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